Biologic medicines approved by the FDA to treat moderate to severe psoriasis include:
Adalimumab (Humira), a TNF-alpha-blocking antibody
Adalimumab-atto (Amjevita), a biosimilar to Humira
Brodalumab (Siliq), a human antibody against interleukins
Etanercept (Enbrel), a TNF-alpha blocker
Etanercept-szzs (Erelzi), a TNF-alpha blocker
Infliximab (Remicade), a TNF-alpha blocker
Ixekizumab (Taltz), an antibody that binds to inflammation-causing protens and interleukins
Secukinumab (Cosentyx), a human antibody against interleukins
Ustekinumab (Stelara), a human antibody against interleukins